Laparoscopic RP: Questions remain about urology's 'Mount Everest'

Reading about the current state of laparoscopic radical prostatectomy related by one of its pioneers may give the impression that this procedure is relatively easy to perform in most patients with prostate cancer (see article, page 1). But it is important to realize that Claude Abbou, MD; Bertrand Guillonneau, MD; Guy Vallencien, MD; and others now have a large clinical experience with the procedure that did not occur overnight. I have been awed by the dedication shown by these French urologists in developing and refining what might be considered the "Mount Everest" of minimally invasive surgery.

Related Videos

Related Content

Advertisement

February 4th 2025

Phase 2 trial launches of opaganib plus darolutamide in mCRPC

Hannah Clarke

The primary end point is 12-month radiographic progression-free survival.

January 29th 2025

Identifying Patients with Intermediate Risk in NMIBC

Max Kates, MD Neal Shore, MD, FACS Tom Jayram, MD

Panelists explore challenges in identification of intermediate risk patients and emphasize importance of risk stratification to improve outcomes in regards to NMIBC.

February 4th 2025

Study points to increasing incidence of advanced prostate cancer in California

Hannah Clarke

The data also showed that mortality plateaued in recent years despite declining in years prior.

January 14th 2025

Episode 2 Podcast: Managing Overactive Bladder: From Dual Diagnoses to Geriatric Challenges

Wayne Kuang, MD Steven Maislos, MD

Panelists discuss how managing overactive bladder in older adults requires a holistic approach that integrates treatment of comorbidities, emerging therapeutic options, and quality-of-life considerations to optimize patient outcomes.

February 3rd 2025

Hundreds of future urologists celebrate Urology Match Day 2025

Hannah Clarke

Overall, 403 medical students and other applicants were matched across 148 urology residency programs nationwide.

February 3rd 2025

Acute toxicity after prostate cancer radiotherapy increases odds of late toxicity

Hannah Clarke

The incidence of late grade 2 or greater GU toxicity at 5 years was 12.5% among those who did experience acute toxicity vs 7.5% among those who did not.

Related Content

Advertisement

February 4th 2025

Phase 2 trial launches of opaganib plus darolutamide in mCRPC

Hannah Clarke

The primary end point is 12-month radiographic progression-free survival.

January 29th 2025

Identifying Patients with Intermediate Risk in NMIBC

Max Kates, MD Neal Shore, MD, FACS Tom Jayram, MD

Panelists explore challenges in identification of intermediate risk patients and emphasize importance of risk stratification to improve outcomes in regards to NMIBC.

February 4th 2025

Study points to increasing incidence of advanced prostate cancer in California

Hannah Clarke

The data also showed that mortality plateaued in recent years despite declining in years prior.

January 14th 2025

Episode 2 Podcast: Managing Overactive Bladder: From Dual Diagnoses to Geriatric Challenges

Wayne Kuang, MD Steven Maislos, MD

Panelists discuss how managing overactive bladder in older adults requires a holistic approach that integrates treatment of comorbidities, emerging therapeutic options, and quality-of-life considerations to optimize patient outcomes.

February 3rd 2025

Hundreds of future urologists celebrate Urology Match Day 2025

Hannah Clarke

Overall, 403 medical students and other applicants were matched across 148 urology residency programs nationwide.

February 3rd 2025

Acute toxicity after prostate cancer radiotherapy increases odds of late toxicity

Hannah Clarke

The incidence of late grade 2 or greater GU toxicity at 5 years was 12.5% among those who did experience acute toxicity vs 7.5% among those who did not.